




BioNMR in Drug Research

Edited by Oliver Zerbe

**Methods
and Principles
in Medicinal
Chemistry**


Volume 16

Edited by
R. Mannhold,
H. Kubinyi,
G. Folkers



BioNMR in Drug Research

Edited by
Oliver Zerbe



Series Editors

Prof. Dr. Raimund Mannhold

Biomedical Research Center
Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstraße 1
40225 Düsseldorf
Germany
raimund.mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

BASF AG Ludwigshafen
c/o Donnersbergstraße 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Department of Applied Biosciences
ETH Zürich
Winterthurer Straße 190
8057 Zürich
Switzerland
folkers@pharma.ethz.ch

Volume Editor

Dr. Oliver Zerbe

Department of Applied Biosciences
ETH Zürich
Winterthurer Straße 190
8057 Zürich
Switzerland
oliver.zerbe@pharma.anbi.ethz.ch

This book was carefully produced. Nevertheless, editors, authors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by

Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

© 2003 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany
Printed on acid-free paper

Typesetting K+V Fotosatz GmbH, Beerfelden

Printing Strauss Offsetdruck GmbH, Mörlenbach

Bookbinding Litges & Dopf Buchbinderei GmbH, Heppenheim

ISBN 3-527-30465-7

BioNMR in Drug Research

Edited by
Oliver Zerbe

Methods and Principles in Medicinal Chemistry

Edited by

R. Mannhold, H. Kubinyi, G. Folkers

Editorial Board

H.-D. Höltje, H. Timmerman,

J. Vacca, H. van de Waterbeemd, T. Wieland

Preface

Some decades have gone since NMR spectroscopy first hit the analytical scene, and yet its capabilities and applications continue to evolve. Originally designed as a way to verify the structure of relatively small compounds, the technology of NMR boomed and became a valuable means for studying protein structure. Traditionally, X-ray crystallography has been used for solving the structure of proteins; however, it is useful only for those that can be coaxed into a crystalline state. The development of multidimensional NMR and more powerful instruments opened the door for solving the structure of proteins and peptides in an aqueous environment, as they exist in biological systems. NMR allows one to observe the physical flexibility of proteins and the dynamics of their interactions with other molecules, a huge advantage when studying the biochemical function of proteins. The structural information, achieved from NMR studies, can be used to understand the function, mechanism of action, and binding specificity of these proteins.

In addition, NMR can be used to design high affinity ligands for proteins using the SAR by NMR approach (Structure Activity Relationships by Nuclear Magnetic Resonance) introduced by Stephen Fesik. Using this method, small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together. The method reduces the amount of chemical synthesis and time required for the discovery of high affinity ligands.

These few remarks highlight that NMR spectroscopy has adapted a central role in drug discovery and design. It is the intention of the present volume to document this role in adequate detail. Accordingly, the book is divided into four larger sections. A methodological section summarizes the technical state of the art including general aspects of spectroscopy; the following section deals in detail with spectroscopic techniques for structure determination of commonly encountered classes of biomolecules. NMR techniques for investigating drug-receptor complexes as well as strategies for drug development using NMR are the topics of the remaining two sections.

The series editors would like to thank the authors and in particular Oliver Zerbe as the volume editor that they devoted their precious time to compiling and structuring the comprehensive information on NMR techniques in drug research. Last, but not least we want to express our gratitude to Frank Weinreich and Gudrun Walter from Wiley-VCH publishers for the fruitful collaboration.

August 2002

Raimund Mannhold, Düsseldorf
Hugo Kubinyi, Ludwigshafen
Gerd Folkers, Zürich

Foreword

Two decades ago, NMR in pharmaceutical industry was mainly used as an analytical tool to validate and identify compounds that were synthesized by medicinal chemists. Following the rapid developments in biomolecular NMR that resulted in the first polypeptide structure being published by the Wüthrich group in the mid eighties, it has thereafter increasingly been used to also determine structures of biomolecules. During the late eighties/early nineties triple-resonance experiments and isotope labeling methods were established which helped to increase the molecular size limits remarkably, and, even more importantly, allowed to more rapidly assign the proton frequencies. While the development of spectroscopic tools still continued, characterized by the advent of TROSY techniques and the use of dipolar couplings, investigations into interactions between drugs or lead candidates and their corresponding receptors were initiated. Early work from Feeney and Roberts in that area was followed by the systematic use of these techniques by the Abott group lead by S. Fesik. In particular, detection of low-affinity ligands has proven to be invaluable in the early development phase of drugs. Accordingly, this book is intended to present an update both in the area of spectroscopic techniques as well as on methodology for screening.

The book is separated into five major sections: One short section on general aspects of spectroscopy, molecular biology and data evaluation is followed by an introduction into the NMR of commonly encountered classes of biomolecules. Thereafter, recent developments in spectroscopic techniques are highlighted. The next section describes experiments and practical aspects useful for the characterization of protein-ligand interactions. The final section presents an account on strategies for drug development using NMR written by experts from pharmaceutical industry.

It is also intended to present techniques which are not routinely applied nowadays but which have the potential to become very useful. Membrane-bound proteins such as G-protein coupled receptors, for example, are important pharmaceutical targets but have so far been very difficult to study by solution-state NMR or single crystal diffraction, the latter mainly due to the enormous difficulties in preparing crystal suitable for diffraction, and the more involved molecular biology to produce them. Solid-state NMR is a technique which may contribute much to that field, and the present progress both in the field of molecular biology as well as in solid-state NMR methodology will certainly stimulate groups to tackle membrane proteins in the future. To provide those readers, which lack experience in that field, with the necessary background, a more detailed introduction to the concepts and applications of solid-state NMR is provided.

The chapters are aiming at providing an overview into a particular field. For a more rigorous description of the experiments, the reader is usually referred to the original literature for which the references are included. A particular emphasis has been placed on practical aspects of work, which originated from the authors' experience with the experiments. As part of this effort, a short chapter on trouble shooting of hardware has been included, in order to make sure that no precious measuring time is wasted. In general, these practical hints are intended for those that decide to move into the field and to provide them with the knowledge necessary to successfully use the tools but should also help to recognize limitations of the techniques.

Biomolecular NMR is a complex technique, which is still rapidly evolving, and people have to learn how the strength of NMR can be exploited best. The editor hopes that the readers will be lucky in choosing the right targets together with the most efficient strategies and wishes that the chapters will help them to do so. Rational drug development is certainly strongly depending upon the input of experimental structural data and hence it is the editor's firm belief that NMR will always play an important role in the drug development process and that new methodology will help to even increase it.

I am deeply grateful to all authors who have patiently responded to my numerous requests for additions and modifications. I would like to especially thank Drs. Marcel Blommers, Wolfgang Jahnke, Werner Klaus, Alfred Ross and Hans Senn for very helpful discussions during the early phase of the book. I would also like to thank Frank Weinreich from Wiley-VCH for the competent help during this project and various publishers for giving the permission to reproduce figures from the original publications. Finally, I would like to thank my wife Katja and my sons Yannick and Benjamin who had to be without me on so many weekends and evenings while I was editing this book. I dedicate this book in love to them.

Zürich, July 2002

Oliver Zerbe

List of Authors

Eva de Alba
NHLBI, NIH
Bethesda, MD 20892
USA
eva@madrid.nhlbi.nih.gov

Reto Bader
Department of Chemistry
University of Cambridge
Unilever Building UB7
Lensfield Road
Cambridge CB12 1EW
United Kingdom
Rub20@cam.ac.uk

Marcel J. J. Blommers
Core Technologies
Novartis Pharma AG
P.O. Box
CH-4002 Basel
Switzerland
marcel_jj.blommers@pharma.novartis.com

Florence Cordier
Divison of Structural Biology
Biozentrum
University of Basel
CH-4056 Basel
Switzerland
florence.cordier@unibas.ch

Silvia Davalli
GlaxoSmithKline Medicines
Research Centre
Via Fleming 4
37135 Verona
Italy
sd6223@gsk.com

Andrew J. Dingley
Department of Biochemistry
and Molecular Biology
University College London
Gower Street
London, WC1E 6BT
United Kingdom
dingley@biochemistry.ucl.ac.uk

Volker Dötsch
Department of Pharmaceutical Chemistry
University of California, San Francisco
513 Parnassus Ave
San Francisco, CA 94143-0446
USA
volker@picasso.ucsf.edu

Matthias Ernst
ETH Zürich
Physical Chemistry
ETH-Hönggerberg
CH-8093 Zürich
Switzerland
maer@nmr.phys.chem.ethz.ch

Erhard Fernholz
Roche Diagnostics GmbH
Nonnenwald 2
D-82372 Penzberg
Germany
erhard.fernholz@roche.com

Radovan Fiala
National Centre for Biomolecular Research
Masaryk University
Kotlářská 2
611 37 Brno
Czech Republic
fiala@chemi.muni.cz

Andreas Flörsheimer
Oncology Research
Novartis Pharma AG
P. O. Box
CH-4002 Basel
Switzerland
andreas.floersheimer@pharma.novartis.com

David Fushman
Center of Biomolecular Structure
and Organization
Department of Chemistry and Biochemistry
University of Maryland
College Park, MD 20742
USA
fushman@wam.umd.edu

Gerd Gemmecker
TU München
Institut für Organische Chemie
und Biochemie II
Lichtenbergstr. 4
D-85747 Garching
Germany
gerd.gemmecker@ch.tum.de

Natalie Goto
Department of Molecular Biology
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
gonat@scripps.edu

Christian Griesinger
Max-Planck-Institut für Biophysikalische
Chemie
Am Fassberg 11
D-37077 Göttingen
Germany
cigr@mpibpc.gwdg.de

Stephan Grzesiek
Division of Structural Biology
Biozentrum
University of Basel
CH-4056 Basel
Switzerland
stephan.grzesiek@unibas.ch

Peter Güntert
Riken Genomics Center
1-7-22 Suehiro, Tsurumi
Yokohama, 230-00-45
Japan
guentert@gsc.riken.go.jp

Markus Heller
Lehrstuhl II für organische Chemie
Technische Universität München
Lichtenbergstrasse 4
85747 Garching
Germany
markus.heller@ch.tum.de

Xuemei Huang
TRIAD Therapeutics, Inc.
5820 Nancy Ridge Drive
San Diego, CA 92121
USA

Hideo Iwai
Institute of Biochemistry
University of Zurich
Winterthurer Strasse 190
CH-8057 Zurich, Switzerland
iwai@access.unizh.ch

Victor A. Jaravine
Division of Structural Biology
Biozentrum
University of Basel
CH-4056 Basel
Switzerland
victor.jaravine@unibas.ch

Wolfgang Jahnke
Core Technologies
Novartis Pharma AG
P.O. Box
CH-4002 Basel
Switzerland
wolfgang.jahnke@pharma.novartis.com

Werner Klaus
Hoffmann-La Roche AG
Dep. PRBT-S
Building 65/514
4070 Basel
Switzerland
werner.klaus.wk1@roche.com

Christopher A. Lepre
Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
USA
lepre@vpharm.com

Mirjam Lerch
Institute of Pharmaceutical Sciences
Department of Applied Biosciences
ETH Zürich
Winterthurer Str. 190
CH-8057 Zürich
Switzerland
mlerch@pharma.anbi.ethz.ch

Kenneth Lundstrom
Bio-Xtal,
Biopole Epalinges
Les Croisettes 22
CH-1066 Epalinges (Lausanne)
Switzerland
kenneth.lundstrom@mepnet.org

Carla Marchioro
GlaxoSmithKline Medicines
Research Centre
Via Fleming 4
I-37135 Verona
Italy
carla.marchioro@gsk.com

Beat H. Meier
ETH Zürich
Physical Chemistry
ETH Hönggerberg
CH-8093 Zürich
Switzerland
beme@nmr.phys.chem.ethz.ch

David Meininger
TRIAD Therapeutics, Inc.
5820 Nancy Ridge Dr.
San Diego, CA 92121
USA

Detlef Moskau
Bruker BioSpin AG
Industriestraße 26
CH-8117 Fällanden
Switzerland
Detlef.Moskau@bruker-biospin.ch

Heiko Patzelt
Department of Chemistry, College of
Science
Sultan Qaboos University
P.O. Box 36, Al-Khod 123
Sultanate of Oman
Patzelt@squ.edu.om

Maurizio Pellecchia
The Burnham Institute
10901 North Torrey Pines Road
La Jolla, CA 92037
USA
mpellecchia@burnham.org

Stefano Provera
GlaxoSmithKline
Medicines Research Centre
Via Fleming 4
I-37135 Verona
Italy
sp15157@gsk.com

Roland Riek
Structural Biology Laboratory
The Salk Institute
La Jolla, CA 92037
USA
riek@sbl.salk.edu

Alfred Ross
Hoffman-La Roche AG
Pharmaceutical Research
CH-4002 Basel
Switzerland
alfred.ross@roche.com

Gordon C.K. Roberts
Biological NMR Centre
Department of Biochemistry
University of Leicester
P.O. Box 138
University Road
Leicester, LE1 9HN
United Kingdom
gcr@le.ac.uk

Simon Rüdisser
Core Technologies
Novartis Pharma AG
P. O. Box
CH-4002 Basel
Switzerland
simon.ruedisser@pharma.novartis.com

Daniel S. Sem
TRIAD Therapeutics, Inc.
5820 Nancy Ridge Dr.
San Diego, CA 92121
USA

Hans Senn
Hoffman-La Roche AG
Pharmaceutical Research
CH-4002 Basel
Switzerland
hans.senn@roche.com

Vladimír Sklenář
National Centre for Biomolecular Research
Masaryk University
Kotlářská 2
611 37 Brno
Czech Republic
sklenar@chemi.muni.cz

Nico Tjandra
NHLBI, NIH
Bethesda, MD 20892
USA
nico@helix.nih.gov

Philip T.F. Williamson
ETH Zürich
Physical Chemistry
ETH Hönggerberg
CH-8093 Zürich
Switzerland
Phil.Williamson@nmr.phys.chem.ethz.ch

Oliver Zerbe
Institute of Pharmaceutical Sciences
Department of Applied Biosciences
ETH Zürich
Winterthurer Str. 190
CH-8057 Zürich
Switzerland
oliver.zerbe@pharma.anbi.ethz.ch

List of Abbreviations

ADME	absorption, distribution, metabolism, excretion
BHK	baby hamster kidney
CD	circular dichroism
CHO	chinese hamster ovary
CMV	cytomegalovirus
COSY	correlation spectroscopy
CSA	chemical shift anisotropy
CSM	chemical shift modulation
DHFR	dihydrofolate reductase
DD	dipole-dipole
DFT	density functional theory
DQ	double quantum
DQC	double-quantum coherence
E.COSY	exclusive correlation spectroscopy
EGF	epidermal growth factor
EPL	expressed protein ligation
FHSQC	fast heteronuclear single-quantum coherence
FIDS	fitting of doublets from singlets
GDP	guanosine diphosphate
HEK	human embryonic kidney
HETCOR	heteronuclear correlation
HMBC	heteronuclear multiple-bond correlation
HMQC	heteronuclear multiple-quantum correlation
HMQC	heteronuclear multiple-quantum correlation
HSQC	heteronuclear single-quantum correlation
HTS	high-throughput screening
IPL	intein-mediated protein ligation
MD	molecular dynamics
MQ	multiple quantum
NOE	nuclear Overhauser effect
PK	pharmacokinetic
PCA	principal component analysis
RDC	residual dipolar coupling

RMSD	root mean square deviation
SAR	structure-activity relationship
SQ	single quantum
TOCSY	total correlation spectroscopy
TROSY	transverse relaxation-optimized spectroscopy
ZQ	zero quantum
ZQC	zero-quantum coherence

Contents

Preface XVII

Foreword XIX

List of Authors XXI

List of Abbreviations XXVII

Part I: Basic Techniques

1	Modern Methods for the Expression of Proteins in Isotopically Enriched Form	1
	<i>Heiko Patzelt, Natalie Goto, Hideo Iwai, Kenneth Lundstrom, and Erhard Fernholz</i>	
1.1	Introduction	1
1.2	Isotope-Labeled Proteins from Hydrolyzates of the Green Alga <i>Scenedesmus obliquus</i>	12
1.2.1	Production of Isotope-Labeled Algal Hydrolyzates	3
1.2.2	Adaptation of the Protein Overproducer to the Algal Medium	4
1.2.3	Preparation of Homogenously Isotope-Labeled Protein by Fermentation on Algal Media	5
1.2.4	Amino Acid-Type Specific Labeling	5
1.2.5	Mass Spectrometric Analysis of the Labeled Amino Acids	6
1.3	Selective Labeling Schemes	6
1.3.1	Reverse-Labeling Schemes	8
1.3.1.1	Selective Protonation of Methyl Groups in ^2H -Labeled Proteins	8
1.3.1.2	Structure Determination of Selectively Methyl Protonated Proteins	10
1.3.1.3	Introducing ^1H , ^{12}C Aromatic Residues into Otherwise ^{13}C Uniformly Labeled Proteins	10
1.3.1.4	Backbone-Labeled Proteins	10
1.3.2	Selective ^{13}C Methyl Group Labeling	11
1.4	Intein-Based Protein Engineering for NMR Spectroscopy	11
1.4.1	Segmental Labeling of Proteins	13
1.4.1.1	Intein-Mediated Protein Ligation (IPL)/Expressed Protein Ligation (EPL) using the IMPACT System	13

1.4.1.2	Reconstitution of Split Inteins	15
1.4.2	Stabilizing Proteins by Intein-Mediated Backbone Cyclization	18
1.4.2.1	<i>In vitro</i> Cyclization of Proteins	18
1.4.2.2	<i>In vivo</i> Cyclization	20
1.4.2.3	Stability Enhancement by Backbone Cyclization	20
1.5	Alternatives to <i>E. coli</i> Expression Systems	20
1.5.1	Expression Vectors	21
1.5.1.1	<i>Halobacterium salinarum</i>	21
1.5.1.2	<i>Saccharomyces cerevisiae</i>	22
1.5.1.3	<i>Schizosaccharomyces pombe</i>	23
1.5.1.4	<i>Pichia pastoris</i>	23
1.5.1.5	Baculovirus	24
1.5.1.6	Transient Mammalian Expression	24
1.5.1.7	Stable Mammalian Expression	24
1.5.1.8	Viral Vectors	25
1.5.2	Comparison of Expression Systems	25
1.5.3	Isotope Labeling and NMR	27
1.5.4	Target Proteins	28
1.6	The Use of Cell-Free Protein Expression for NMR Analysis	29
1.6.1	The Cell-Free Protein Expression Systems RTS	30
1.6.2	From PCR Product to ¹⁵ N-Labeled Protein	31
1.6.3	Discussion and Outlook	33
1.7	References	34
2	Structure Calculation Using Automated Techniques	39
	<i>Peter Güntert</i>	
2.1	Introduction	39
2.2	Conformational Constraints for NMR Structure Calculations	39
2.2.1	Constraints from Covalent Structure	40
2.2.2	Steric Repulsion	40
2.2.3	Distance Constraints from Nuclear Overhauser Effects	40
2.2.4	Hydrogen Bond Distance Constraints	43
2.2.5	Torsion Angle Constraints from Chemical Shifts	43
2.2.6	Torsion Angle Constraints from Scalar Coupling Constants	44
2.2.7	Orientation Constraints	45
2.3	Structure Calculation Algorithms	46
2.3.1	Simulated Annealing by Molecular Dynamics Simulation in Cartesian Space	46
2.3.2	Torsion Angle Dynamics	48
2.4	Automated NOESY Assignment	52
2.4.1	The NOESY Assignment Problem	52
2.4.2	Semi-Automatic Methods	53
2.4.3	General Principles of Automatic NOESY Assignment	53
2.4.4	Requirements on Input Data	54
2.4.5	Overview of Algorithms	55